Collect plasma and other specimens from patients who are newly diagnosed with NSCLC or with drug-resistant and plan to receive gene detection to complete the diagnostic test for liquid biopsy .Participants who come from diagnostic test and plan to receive tyrosine kinase inhibitors (TKI) therapy will be collected plasma and other specimens every month during the regiments and monitor the changes of driver motion to predict the prognosis of targeted therapy.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
cohort 1
patients newly diagnosed with NSCLC confirmed by tissue biopsy and going to receive the detection of gene mutation or patients have obtained drug-resistance after receiving molecular target therapy and plan to re-biopsy.
Age ≥ 18 years
newly diagnosed patients have not received TKI and chemotherapy
patients who are drug-resistant have not received next-generation TKI
patients from cohort1 with sensitive driver mutation and plan to receive TKI therapy
patients will have regular follow-up in Chinese people liberation army general hospital every month.
You may not be if
patients who have more than one type of carcinoma
patients who reject to sign the informed consent from
cohort 2
patients who are refused to provide the informed consent from
